10x Genomics, Inc. Stock Research

Market Summary

USD50.23+1.19

Market Closed

2.43%

TXG Alerts

Losses in recent quarter

TXG Stock Price

TXG RSI Chart

TXG Valuation

Market Cap

5.8B

Price/Earnings (Trailing)

-34.86

Price/Sales (Trailing)

11.2

EV/EBITDA

-40.84

Price/Free Cashflow

-35.01

TXG Price/Sales (Trailing)

TXG Profitability

Operating Margin

76.69%

EBT Margin

-31.36%

Return on Equity

-20.6%

Return on Assets

-16.13%

Free Cashflow Yield

-2.86%

TXG Fundamentals

TXG Revenue

Revenue (TTM)

516.4M

Revenue Y/Y

8.85%

Revenue Q/Q

19.2%

TXG Earnings

Earnings (TTM)

-166.0M

Earnings Y/Y

6.69%

Earnings Q/Q

58.93%

Price Action

52 Week Range

23.8183.34

(Low)(High)

Last 7 days

-0.2%

Last 30 days

2.8%

Last 90 days

46.7%

Trailing 12 Months

-27.2%

TXG Financial Health

Current Ratio

4.85

TXG Investor Care

Shares Dilution (1Y)

2.38%

Diluted EPS (TTM)

-1.46

Peers (Alternatives to 10x Genomics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
A	38.9B	6.8B	-7.12%	-2.94%	31.04	5.68	8.37%	3.64%
ILMN	34.8B	4.6B	9.07%	-35.87%	-7.89	7.58	1.28%	-677.95%
MTD	32.3B	3.9B	0.30%	5.82%	37.04	8.24	5.43%	13.46%
WAT	17.7B	3.0B	-6.58%	-7.74%	25.05	5.97	6.68%	2.15%
PKI	16.1B	3.3B	-0.99%	-28.86%	28.31	4.87	-34.64%	-39.65%
MID-CAP
SMALL-CAP
PACB	2.2B	128.3M	3.11%	-0.62%	-6.93	16.97	-1.69%	-73.40%
ADPT	1.2B	185.3M	-4.53%	-36.18%	-6.03	6.51	20.06%	3.42%
NSTG	404.1M	127.3M	-11.64%	-74.22%	-2.53	3.18	-12.28%	-38.43%
QTRX	394.4M	105.5M	-10.11%	-62.94%	-4.08	3.74	-4.55%	-67.63%
BNGO	326.9M	27.8M	-22.54%	-54.36%	-2.47	11.76	54.62%	-83.06%
CDXS	255.3M	138.6M	-29.45%	-81.04%	-7.6	1.84	32.30%	-57.86%
HBIO	130.5M	113.3M	8.01%	-46.55%	-13.71	1.15	-4.68%	-3204.17%
PSNL	121.4M	65.0M	-18.24%	-68.45%	-1.07	1.87	-23.92%	-73.73%
CSBR	57.9M	54.1M	-2.96%	-46.49%	536.06	1.07	21.80%	-72.38%

Financials for 10x Genomics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	2.5%	516,409,000	503,707,000	497,932,000	499,165,000	490,490,000
Gross Profit	0.9%	396,023,000	392,550,000	392,634,000	416,656,000	416,399,000
Operating Expenses	1.9%	563,967,000	553,228,000	529,195,000	500,428,000	468,652,000
S&GA Expenses	3.1%	298,300,000	289,290,000	277,965,000	267,331,000	257,560,000
EBITDA	0.2%	-136,127,000	-136,357,000	-113,325,000	-60,963,000	-31,731,000
EBITDA Margin	2.6%	-0.26	-0.27	-0.23	-0.12	-0.06
Earnings Before Taxes	-0.3%	-161,971,000	-161,553,000	-138,166,000	-84,293,000	-53,715,000
EBT Margin	2.2%	-0.31	-0.32	-0.28	-0.17	-0.11
Interest Expenses	-16.2%	476,000	568,000	673,000	773,000	866,000
Net Income	0.7%	-166,000,000	-167,234,000	-142,491,000	-89,085,000	-58,223,000
Net Income Margin	3.2%	-0.32	-0.33	-0.29	-0.18	-0.12
Free Cahsflow	-2.6%	-165,267,000	-161,069,000	-161,376,000	-128,642,000	-122,651,000

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	3.3%	1,029	996	1,002	1,003	1,019
Current Assets	0.9%	635	629	666	697	748
Cash Equivalents	-5.9%	227	242	282	320	596
Inventory	3.8%	82.00	79.00	71.00	64.00	60.00
Net PPE	12.3%	289	258	223	190	169
Goodwill	0%	5.00	5.00	5.00	5.00	5.00
Liabilities	1.3%	223	220	218	197	201
Current Liabilities	3.2%	131	127	118	94.00	110
Shareholder's Equity	3.9%	806	776	784	807	818
Retained Earnings	-1.7%	-1,029	-1,012	-970	-905	-863
Additional Paid-In Capital	2.6%	1,839	1,793	1,758	1,715	1,681
Accumulated Depreciation	40.4%	69.00	49.00	-	-	-
Shares Outstanding	0.9%	115	114	114	113	113

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	19.1%	-33.61	-41.52	-58.18	-38.09	-21.37
Share Based Compensation	11.5%	137	123	115	106	96.00
Cashflow From Investing	-1.6%	-350	-345	-332	-319	-106
Cashflow From Financing	-19.8%	16.00	20.00	24.00	34.00	35.00

Risks for TXG

What is the probability of a big loss on TXG?

86.6%

Probability that 10x Genomics stock will be more than 20% underwater in next one year

64.0%

Probability that 10x Genomics stock will be more than 30% underwater in next one year.

58.1%

Probability that 10x Genomics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TXG drawdown profile look like?

Y-axis is the maximum loss one would have experienced if 10x Genomics was unfortunately bought at previous high price.

Drawdowns

Returns for TXG

Cumulative Returns on TXG

-4.2%

3-Year Cumulative Returns

Which funds bought or sold TXG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	BAILLIE GIFFORD & CO	added	1.88	72,998,400	313,465,000	0.33%
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	reduced	-0.05	76,760	353,760	-%
2023-03-06	Rockefeller Capital Management L.P.	added	319	358,000	439,000	-%
2023-03-06	NORTH STAR ASSET MANAGEMENT INC	added	4.78	332,981	1,309,980	0.08%
2023-02-28	Voya Investment Management LLC	added	0.01	282,450	1,290,450	-%
2023-02-24	NATIXIS	new	-	74,155	74,155	-%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	unchanged	-	555,000	2,547,000	0.03%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	reduced	-8.51	1,402	9,402	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-	-25,000	-	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	reduced	-7.41	-89.00	911	-%

Latest Funds Activity

Are funds buying TXG calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own TXG

No. of Funds

TXG Alerts

Losses in recent quarter

10x Genomics News

Schedule 13G FIlings of 10x Genomics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	venrock associates vi, l.p.	4.9%	4,828,247	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.81%	8,420,011	SC 13G/A
Feb 08, 2023	morgan stanley	10.4%	9,894,979	SC 13G/A
Feb 01, 2023	blackrock inc.	5.6%	5,319,179	SC 13G/A
Jan 18, 2023	baillie gifford & co	9.00%	8,602,235	SC 13G/A
Sep 12, 2022	morgan stanley	10.9%	10,341,753	SC 13G/A
May 09, 2022	blackrock inc.	10.9%	10,227,673	SC 13G
Feb 14, 2022	venrock associates vi, l.p.	5.1%	4,828,247	SC 13G/A
Feb 09, 2022	vanguard group inc	8.25%	7,554,042	SC 13G/A

TXG Fair Value

10x Genomics fair value in different scenarios

The table shows the Fair Value estimates for 10x Genomics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	2.48 -95.06%	3.37 -93.29%	6.07 -87.92%	10.16 -79.77%	13.70 -72.73%
Current Inflation	2.42 -95.18%	3.20 -93.63%	5.55 -88.95%	9.05 -81.98%	12.07 -75.97%
Very High Inflation	2.33 -95.36%	3.00 -94.03%	4.93 -90.19%	7.75 -84.57%	10.19 -79.71%

Historical 10x Genomics Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of 10x Genomics

View All Filings

Date Filed	Form Type	Document
Mar 23, 2023	4	Insider Trading
Mar 23, 2023	4	Insider Trading
Mar 23, 2023	4	Insider Trading
Mar 23, 2023	4	Insider Trading
Mar 16, 2023	4	Insider Trading
Mar 09, 2023	4	Insider Trading
Feb 24, 2023	4	Insider Trading
Feb 24, 2023	4	Insider Trading
Feb 24, 2023	4	Insider Trading
Feb 16, 2023	10-K	Annual Report

Latest Insider Trading transactions for TXG

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-21	Saxonov Serge	acquired	-	-	36,387	chief executive officer
2023-03-21	Hindson Benjamin J.	acquired	-	-	36,387	see remarks
2023-03-21	Wilbur James	acquired	-	-	14,555	chief commercial officer
2023-03-21	McAnear Justin J.	acquired	-	-	25,991	chief financial officer
2023-03-14	Saxonov Serge	sold	-97,755	48.8779	-2,000	chief executive officer
2023-03-07	Saxonov Serge	gifted	-	-	-260	chief executive officer
2023-02-22	Saxonov Serge	sold	-92,689	47.7533	-1,941	chief executive officer
2023-02-22	McAnear Justin J.	sold	-59,452	47.7533	-1,245	chief financial officer
2023-02-22	Hindson Benjamin J.	sold	-83,186	47.7533	-1,742	see remarks
2022-12-14	Hindson Benjamin J.	acquired	172,701	5.04	34,266	see remarks

About 10x Genomics

Serge Saxonov

www.10xgenomics.com

1240

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 516,409	$ 490,490	$ 298,845
Cost of revenue	120,386	74,091	58,468
Gross profit	396,023	416,399	240,377
Operating expenses:
Research and development	265,667	211,752	123,375
In-process research and development	0	0	447,548
Selling, general and administrative	298,300	257,560	202,326
Accrued contingent liabilities	0	(660)	1,270
Total operating expenses	563,967	468,652	774,519
Loss from operations	(167,944)	(52,253)	(534,142)
Other income (expense):
Interest income	6,647	206	1,532
Interest expense	(476)	(866)	(1,682)
Other (expense) income, net	(198)	(802)	1,337
Loss on extinguishment of debt	0	0	(1,521)
Total other income (expense)	5,973	(1,462)	(334)
Loss before provision for income taxes	(161,971)	(53,715)	(534,476)
Provision for income taxes	4,029	4,508	8,255
Net loss	$ (166,000)	$ (58,223)	$ (542,731)
Net loss per share, basic (in dollars per share)	$ (1.46)	$ (0.53)	$ (5.37)
Net loss per share, diluted (in dollars per share)	$ (1.46)	$ (0.53)	$ (5.37)
Weighted-average shares used to compute net loss per share, basic (in shares)	113,858,684	110,347,937	101,151,675
Weighted-average shares used to compute net loss per share, diluted (in shares)	113,858,684	110,347,937	101,151,675

TXG Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 219,746	$ 587,447
Marketable securities	210,238	0
Restricted cash	2,633	1,028
Accounts receivable, net	104,211	85,254
Inventory	81,629	59,966
Prepaid expenses and other current assets	16,578	13,896
Total current assets	635,035	747,591
Property and equipment, net	289,328	169,492
Restricted cash	4,974	7,598
Operating lease right-of-use assets	69,882	60,918
Goodwill	4,511	4,511
Intangible assets, net	22,858	25,397
Other noncurrent assets	2,392	3,319
Total assets	1,028,980	1,018,826
Current liabilities:
Accounts payable	21,599	17,351
Accrued compensation and related benefits	32,675	31,626
Accrued expenses and other current liabilities	59,779	50,909
Deferred revenue	7,867	5,340
Operating lease liabilities	9,037	5,131
Total current liabilities	130,957	110,357
Accrued license fee, noncurrent	0	5,814
Operating lease liabilities, noncurrent	86,139	76,847
Other noncurrent liabilities	6,141	8,240
Total liabilities	223,237	201,258
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2022 and December 31, 2021	0	0
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 115,195,009 (Class A 96,527,754, Class B 18,667,255) and 112,514,977 (Class A 92,868,512, Class B 19,646,465) shares issued and outstanding as of December 31, 2022 and 2021	2	2
Additional paid-in capital	1,839,397	1,680,865
Accumulated deficit	(1,029,321)	(863,321)
Accumulated other comprehensive income (loss)	(4,335)	22
Total stockholders’ equity	805,743	817,568
Total liabilities and stockholders’ equity	$ 1,028,980	$ 1,018,826